Data monitoring committees for clinical trials evaluating treatments of COVID-19
The first cases of coronavirus disease 2019 (COVID-19) were reported in December 2019 and the outbreak of SARS-CoV-2 was declared a pandemic in March 2020 by the World Health Organization. This sparked a plethora of investigations into diagnostics and vaccination for SARS-CoV-2, as well as treatments for COVID-19. Since COVID-19 is a severe disease associated with a high mortality, clinical trials in this disease should be monitored by a data monitoring committee (DMC), also known as data safety monitoring board (DSMB). DMCs in this indication face a number of challenges including fast recruitment requiring an unusually high frequency of safety reviews, more frequent use of complex designs and virtually no prior experience with the disease. In this paper, we provide a perspective on the work of DMCs for clinical trials of treatments for COVID-19. More specifically, we discuss organizational aspects of setting up and running DMCs for COVID-19 trials, in particular for trials with more complex designs such as platform trials or adaptive designs. Furthermore, statistical aspects of monitoring clinical trials of treatments for COVID-19 are considered. Some recommendations are made regarding the presentation of the data, stopping rules for safety monitoring and the use of external data. The proposed stopping boundaries are assessed in a simulation study motivated by clinical trials in COVID-19.
Code (0)
등록된 구현이 없습니다.
Similar Papers 제목 키워드 기반
Monitoring Fidelity of Online Reinforcement Learning Algorithms in Clinical Trials
Online reinforcement learning (RL) algorithms offer great potential for personalizing treatment for participants in clinical trials. However, deploying an online, autonomous algorithm in the high-stakes healthcare settin…
reinforcement-learningReinforcement LearningReinforcement Learning (RL)CaresAI at CT-DEB26: Detecting Dosing Errors In Clinical Trials Using Domain-Specific Transformer Embeddings and Classification Models
Medication errors, particularly dosing errors in clinical trials (CT), can lead to patient harm, adverse drug events and worse patient outcomes. Dosing errors are preventable, and early identification can improve trial i…
A parallel collection of clinical trials in Portuguese and English
Parallel collections of documents are crucial resources for training and evaluating machine translation (MT) systems. Even though large collections are available for certain domains and language pairs, these are still sc…
Machine TranslationSentenceTranslationThe Framework That Survives Bad Models: Human-AI Collaboration For Clinical Trials
Artificial intelligence (AI) holds great promise for supporting clinical trials, from patient recruitment and endpoint assessment to treatment response prediction. However, deploying AI without safeguards poses significa…
Utilizing ChatGPT to Enhance Clinical Trial Enrollment
Clinical trials are a critical component of evaluating the effectiveness of new medical interventions and driving advancements in medical research. Therefore, timely enrollment of patients is crucial to prevent delays or…
Language ModelingLanguage ModellingLarge Language ModelRetrieval